Skip to Content

XOMA Royalty Corp XOMA

Morningstar Rating
$27.30 −0.11 (0.40%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

XOMA is trading at a 514% premium.
Price
$27.21
Fair Value
$43.52
Uncertainty
Extreme
1-Star Price
$948.17
5-Star Price
$37.13
Economic Moat
Zlmw
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if XOMA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$27.41
Day Range
$27.3027.99
52-Week Range
$13.4829.00
Bid/Ask
$27.43 / $27.67
Market Cap
$317.73 Mil
Volume/Avg
3,190 / 18,949

Key Statistics

Price/Earnings (Normalized)
Price/Sales
54.25
Dividend Yield (Trailing)
1.97%
Dividend Yield (Forward)
7.87%
Total Yield
1.97%

Company Profile

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
13

Comparables

Valuation

Metric
XOMA
SLRN
TNGX
Price/Earnings (Normalized)
Price/Book Value
3.881.003.96
Price/Sales
54.2526.23
Price/Cash Flow
Price/Earnings
XOMA
SLRN
TNGX

Financial Strength

Metric
XOMA
SLRN
TNGX
Quick Ratio
9.4213.088.03
Current Ratio
9.4513.278.23
Interest Coverage
Quick Ratio
XOMA
SLRN
TNGX

Profitability

Metric
XOMA
SLRN
TNGX
Return on Assets (Normalized)
−5.64%−28.15%−23.42%
Return on Equity (Normalized)
−9.42%−35.30%−38.32%
Return on Invested Capital (Normalized)
−6.32%−41.97%−35.16%
Return on Assets
XOMA
SLRN
TNGX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
QphxwjtlHly$579.2 Bil
Vertex Pharmaceuticals Inc
VRTX
CwvtxnbQlstm$126.0 Bil
Regeneron Pharmaceuticals Inc
REGN
RfflxzqStyljc$117.6 Bil
Moderna Inc
MRNA
FlsgnstsvYwpc$46.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
ThhvldbqyBbkwd$29.9 Bil
argenx SE ADR
ARGX
LkbntscHzzg$27.7 Bil
BioNTech SE ADR
BNTX
FdtctqrxTmfs$20.8 Bil
Biomarin Pharmaceutical Inc
BMRN
LgczlwhqHdwtyt$15.8 Bil
United Therapeutics Corp
UTHR
RkqwjfmfBjrjz$14.6 Bil
Incyte Corp
INCY
CpvhgmzrgXjcwn$12.9 Bil

Sponsor Center